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Abstract
Objective
To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington’s
disease (HD).
Methods
In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals
with HD and clinical signs of apathy according to the Structured Clinical Interview for Apa-
thy—Dementia (SCIA-D), but not depression (n = 40) were randomized to receive either
bupropion 150/300mg or placebo daily for 10 weeks. The primary outcome parameter was
a significant change of the Apathy Evaluation Scale (AES) score after ten weeks of treat-
ment as judged by an informant (AES-I) living in close proximity with the study participant.
The secondary outcome parameters included changes of 1. AES scores determined by
the patient (AES-S) or the clinical investigator (AES-C), 2. psychiatric symptoms (NPI,
HADS-SIS, UHDRS-Behavior), 3. cognitive performance (SDMT, Stroop, VFT, MMSE), 4.
motor symptoms (UHDRS-Motor), 5. activities of daily function (TFC, UHDRS-Function),
and 6. caregiver distress (NPI-D). In addition, we investigated the effect of bupropion on
brain structure as well as brain responses and functional connectivity during reward pro-
cessing in a gambling task using magnetic resonance imaging (MRI).
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Results
At baseline, there were no significant treatment group differences in the clinical primary and
secondary outcome parameters. At endpoint, there was no statistically significant difference
between treatment groups for all clinical primary and secondary outcome variables. Study
participation, irrespective of the intervention, lessened symptoms of apathy according to the
informant and the clinical investigator.
Conclusion
Bupropion does not alleviate apathy in HD. However, study participation/placebo effects
were observed, which document the need for carefully controlled trials when investigating
therapeutic interventions for the neuropsychiatric symptoms of HD.
Trial registration
ClinicalTrials.gov 01914965
Introduction
Apathy is a common behavioral syndrome in neuropsychiatric disorders with prefrontal cor-
tex (PFC) and basal ganglia (BG) pathology, such as Huntington’s disease (HD) [1, 2]. It is
broadly defined as the primary absence of motivation, lack of initiative and drive, as well as
emotional indifference [3]. Apathy can be divided into three major syndrome domains—defi-
cient emotional-affective function, cognitive function, or auto-activation [2].
In HD, apathy is the most common neuropsychiatric syndrome that correlates directly with
disease progression [4–6]. Loss of dopamine (DA) receptor expression in fronto-striatal cir-
cuits was proposed as a key pathophysiological mechanism of apathy in HD [7, 8]. Neurode-
generation begins in the striatum as early as 15 years prior to motor onset, and then extends to
frontal and PFC cortex regions [9–11]. Pathological changes in the orbital and medial PFC
and the projections to limbic brain regions, predominantly the ventral striatum (VS), have
been associated with the development of apathy in HD [2]. Magnetic resonance imaging
(MRI) is capable of measuring atrophy [12–14] as well as alterations in mesolimbic DA pro-
cesses [15, 16], which are linked to anticipation and processing of reward or punishment. In
premanifest HD patients, an aberrant ventral striatal response during a monetary incentive
delay task has been observed [17].
Despite of the high prevalence and disease burden of apathy in HD, research on therapeutic
options for apathy is rare, and no effective treatment is at hand [18, 19]. This is the first con-
trolled trial (CT) on the treatment of apathy in HD. It was the aim of this trial to evaluate the
efficacy and safety of bupropion in the treatment of apathy in HD. We chose the antidepres-
sant bupropion for its mode of action of blocking norepinephrine and DA reuptake, thereby
potentially increasing DA neurotransmission in areas relevant for apathy. In addition, several
single case reports and results of small series suggested the effectiveness of bupropion for the
treatment of apathy in HD and other neurodegenerative diseases [20–22]. In addition, we
investigated the effect of bupropion on DA-associated reward processing in an established
gambling task using fMRI [23, 24].
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Materials and methods
ACTION-HD (Apathy cure through Bupropion in Huntington’s disease) is a multi-center,
randomized, double-blind, placebo-controlled, 2x2 crossover phase 2b investigator-initiated
trial (IIT) that was conducted at four sites in Germany between May 2012 (recruitment of first
patient) and May 2014 (last patient leaving the trial). The ACTION-HD trial was registered at
the EudraCT clinical trial register (EudraCT number 2009-013698-16) on 24th March 2011
prior to inclusion of the first patient. We later registered the trial at clinicaltrials.gov. The
authors confirm that all ongoing and related trials for this drug/intervention are registered.
The protocol for this trial is available as supporting information; see S1 Clinical trial protocol.
Ethics statement
The study was registered and approved by the German Competent Authorities (Bundesinstitut
fu¨r Arzneimittel und Medizinprodukte (registration number 61-3910-4037522; 16.01.2012)
and the Ethics Commission of the State of Berlin (Ethik-Kommission des Landes Berlin, Land-
esamt fu¨r Gesundheit und Soziales; registration number 11/0351- ZS EK; 27.01.2012), Berlin,
Germany, as well as the institutional review boards of the Universities of Bochum, Mu¨nster
and Ulm (Clinical Trial protocol version 1.1. [17.11.2012], version 2.0 [amendment 2;
22.02.13]; patient informed consent form version 2.0 [17.11.2011], version 3.0 [amendment 2;
22.02.13]; informant informed consent form version 1.0 [17.11.2011]). The study was con-
ducted in accordance with the ethical principles laid out in the Declaration of Helsinki (1996)
and consistent with Good Clinical Practice. All study participants provided informed consent
before any study-related procedures were undertaken.
Study participants
After signing the informed consent form, genetically verified HD patients aged 25 to 75 years
and informants were included in the trial. Apathy was ascertained by the Structured Clinical
Interview for Apathy—Dementia (SCIA-D). A caregiver living in close proximity to the patient
had to participate as informant. Patients with clinically significant depression (NPI depression
score >4), schizophreniform psychosis, a Mini-Mental State Examination (MMSE) < 18,
marked chorea bucco-oro-lingual, of face, trunk or extremities, active suicidality based on the
answer “yes” to questions 4 and 5 of the “suicidal ideation” section of the Columbia-Suicide
Severity Rating Scale (C-SSRS), or treatment with antipsychotics other than tiapride, MAO-B
inhibitors, amantadine, levodopa, D- or D,L-amphetamine or psychostimulants within 1
month prior to the first dose were excluded. A full list of inclusion and exclusion criteria is
provided in S1 Clinical trial protocol in the supporting information. The allocation to either of
two treatment arms was based on a central randomization code generated by means of the ran-
domization procedure of nQuery 7.0. and performed by the study biometrician (PS).
Primary and secondary objectives and sample size justification
The primary objective was to determine the influence of bupropion compared to placebo on
the change of apathy as quantified by the informant-based Apathy Evaluation Scale (AES)-I,
where I [informant] is a family member or friend familiar with the daily activities of the subject
(score: 18–72 points; adjusted for the baseline values at week 0 or 13, respectively). Due to lack
of published data, the power calculation was based on an unpublished patient cohort (n = 50)
followed at the Centre for Brain Repair, University of Cambridge, UK (data generously pro-
vided by Sarah L. Mason and Roger A. Barker) for three years, where the AES-I showed a
mean score of 31 points (standard deviation SD = 15.6). We defined clinically significant
Bupropion does not reduce apathy in HD
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improvement as a 35% reduction of the mean AES-I score and calculated an absolute effect
size of 0.3531 points = 10.85 points. An estimate of 10 points was used for sample size deter-
mination and a within subjects SD of 15.0 was assumed. Accordingly, with a sample size in
each group of 19 and a 2x2 crossover design, we would have 80% power to detect a difference
in means of 10.00 (the difference between a Treatment 1 mean, μ1, of 31 and a Treatment 2
mean, μ2, of 21) assuming that the crossover ANOVA
p
MSE is 15.00 (the standard deviation
of differences is 21.21) using a two group t-test (Crossover ANOVA) with a 0.05 two-sided sig-
nificance level. In order to account for potential dropouts, we decided to randomize 40
patients. Sample size calculation was performed with nQuery 7.0.
The secondary objectives included an assessment of: 1. the safety and tolerability of bupro-
pion in HD, 2. the influence of bupropion compared to placebo on the change of apathy as
quantified by the AES-C (clinician) or the AES-S (self), and the NPI and UHDRS apathy
scores, 3. the change of neuropsychiatric symptoms (UHDRS, HADS-SIS), 4. the change of
cognitive performance (UHDRS and MMSE), 5. the total motor score (UHDRS), 6. the change
of activities of daily living (UHDRS), 7. the change of the NPI caregivers’ distress score
(NPI-D), and 8. the change of VS and ventromedial PFC activation in response to a gambling
task as quantified by fMRI.
Dosing and study plan
Study participants and informants took part in 8 study visits S1 Fig. Prior to and after cross-
over (week 11), all study participants received once daily 150 mg bupropion or placebo for 2
weeks, followed by 300 mg bupropion or placebo per day for 8 weeks. In the case of intolerable
side effects after the dose increase to 300 mg bupropion or placebo, dosing was reduced to 150
mg and maintained for the duration of the treatment arm.
Assessments
Assessment sequence: Apathetic HD patients are likely to have progressed disease [5],
restricted cognitive resources, a short attention span and may experience fatigue during study-
related procedures. We therefore designed a hierarchy of assessments that took these potential
limitations into account.
Assessment of demographic characteristics including medical history, concurrent medica-
tion and physical examination was performed in a structured fashion based on the EHDN plat-
form, which was approved by the institutional review boards of the participant centers for the
observational REGISTRY study of the EHDN.
Structured Clinical Interview for Apathy—Dementia (SCIA-D). To diagnose apathy
and rate the severity of apathy, the SCIA-D was performed at screening, prior to and after each
treatment interval. The SCIA-D was originally validated in patients with AD. It assesses seven
domains relative to the individual’s previous level of functioning and incorporates the judg-
ment of the informant [3, 25]. A German version (Translation: S. Forstmeier, M. Mortby,
2008) authorized by S.E. Starkstein (University of Western Australia, Australia) was used.
Apathy Evaluation Scale (AES). To rate symptoms of apathy, the AES was filled in by the
informant (AES-I; primary outcome variable), the study participant (AES-S), and the clinical
investigator (AES-C) after a semi-structured clinical interview of participant and informant by
the clinical investigator at the beginning of each study visit. Participant and informant had to
perform the AES separately. Both were instructed not to discuss the answers. The AES scale
consists of 18 items, each of which is assessed on a four-point Likert scale, so that the total
score ranges from 0 to 54 [26, 27]. The AES was not used as an inclusion criterion, as there is
no validated cut-off for the presence of clinically relevant apathy in HD. To ensure uniformity
Bupropion does not reduce apathy in HD
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of SCIA-D and AES procedures, we produced a teaching video. In addition, study personnel
were trained in published guidelines for performance [27]. To minimize inter-rater variability,
virtually every study participant was rated by the same clinical investigator with longstanding
experience in HD during the entire course of the study.
Neuropsychiatric Inventory (NPI). To exclude comorbid depression, a “depression/
dysphoria” score of4 on the NPI was required for study inclusion (maximum score is 12
[frequency x severity]). To evaluate effects and side effects of the study medication, the
domains “depression/dysphoria”, “apathy/indifference” and “irritability/lability” were assessed
prior to and after each treatment episode. In addition, caregiver distress (NPI-D) was assessed
from 0 (not at all) to 5 (extremely).
The Hospital Anxiety and Depression Scale combined with the Snaith Irritability Scale
(HADS-SIS). To test for symptoms of depression and signs of irritability, the HADS-SIS was
performed prior to and after each treatment episode. The HADS is a self-report questionnaire
that consists of 14 items rating symptoms of depression (7 items) and anxiety (7 items). The
SIS rates inward and outward irritability (8 items). Each item is rated on a four-point scale.
Unified Huntington’s Disease Rating Scale (UHDRS)-99. The UHDRS-99 was per-
formed prior to and after each treatment episode. The UHDRS-99 is an extension and update
of the UHDRS, the most commonly used and validated clinical rating scale to assess motor
(including chorea and dystonia), psychiatric, and cognitive (Stroop, Verbal Fluency Test, Sym-
bol Digit Modalities Test) symptoms of HD, and to determine functional capacity [28].
Columbia-Suicide Severity Rating Scale (C-SSRS). To exclude suicidal ideation or behav-
ior, this semi-structured scale was performed during every study visit and telephone interview.
Mini Mental Status Examination (MMSE). To assess the cognitive state of the study par-
ticipant, the MMSE was administered prior to and after every treatment episode.
Structural and functional magnetic resonance imaging
Gambling task. To assess brain responses and functional connectivity during reward pro-
cessing by fMRI, an established gambling task known to elicit strong dopaminergic responses
in the VS was used [24, 29]. A detailed description of MRI parameters, determination of
regions of interest (ROI), gambling task paradigm and the applied image-processing pipeline
is provided in the S1 Supplemental methods and S2–S4 Figs.
Data collection and statistical analysis
Data collected on each patient were recorded on an electronic case report form (eCRF) based
on the EHDN REGISTRY platform. During the study, a 100% monitoring was performed in
all centres and eCRF data entries were checked using computerized and manual means to
identify problem fields. All study-related documentation including the study master file was
collected in an ACTION-HD study section of the EHDN web portal accessible to all study per-
sonnel. During the entire study, weekly telephone conferences were held by the study coordi-
nation team.
Statistical analysis. For efficacy analysis, the confirmatory inferential statistical evaluation
of the primary target parameter was based on a linear mixed effects model with the AES-I
score as dependent variable. The model used treatment group and period as fixed factors, and
the baseline AES-I score as covariate. Random effects were introduced for the intercepts, thus
taking the correlation within participants into account. All secondary efficacy variables were
primarily evaluated by using descriptive statistics. If applicable, a similar analysis was per-
formed for secondary variables in an explanatory manner. A detailed description of image
analysis procedures is provided in the S1 Supplemental methods. An excerpt of the data that
Bupropion does not reduce apathy in HD
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will allow full analysis of all results shown in the manuscript except for patient-relevant data
that are protected by confidentiality regulations are available to all interested researchers by
contacting the EHDN Scientific and Bioethics Advisory Committee (SBAC) at actionhd_data-
request@euro-hd.net.
Safety analysis. The safety analysis was performed as outlined in the study protocol (S1
Clinical trial protocol, page 23–30). After the last patient left the study and prior to the data-
base closure, protocol deviations were assessed by the site investigators during a blind data
review meeting in April 2014 and classified as “minor” or “major” based on joint decisions.
Results
Between May 2012 and October 2013, 40 apathetic HD patients were randomized into two
treatment groups (20/20) Fig 1. The subject characteristics are summarized in Table 1. Eigh-
teen study participants consented to participate in the adjunct MRI study. The last study par-
ticipant finished the study in April 2014. The study database was locked on May 30, 2014.
Other than duration of disease (group 1: 8.4 ± 3.6 years vs. group 2: 5.5 ± 2.4 years; p<0.05),
there were no statistically significant treatment group differences for any demographic param-
eter or baseline values of primary or secondary outcome variables Table 1.
A first important observation of the study was that the study participants rated their symp-
toms of apathy (AES-S) as significantly less severe than the caregivers (AES-I; t (df = 38) =
-6.0504, p<0.001) or the clinical investigators (AES-C; t (df = 38) = -5.6101, p<0.001) Table 1.
Due to major protocol violations, two study participants had to be excluded from the per
protocol analysis, because one did not follow the washout and crossover medication sequence
between visit 4 and visit 4a, and the other took less than 80% of the study medication during the
treatment period. Four participants discontinued the study; two for unwillingness to resume
study visits, and one because of increased irritability while on bupropion. A fourth participant
discontinued the study due to mood changes (cf. severe adverse events (SAEs), participant five).
As for the safety and tolerability of bupropion, 21 of 40 study participants had at least one
of 56 AEs. Five AEs were rated as severe and 11 AEs were rated as moderate. The five SAEs
resulted in hospitalizations: two after a fall, in one case with a shoulder fracture and an ensuing
depression, a third for an elective varicose vein stripping, all on placebo. The fourth participant
with a SAE was hospitalized after a short episode of lack of responsiveness three days after the
ending of bupropion treatment (visit 4; S1 Fig). A fifth participant was hospitalized due to an
increased instability of mood, irritability and aggression which evolved one day prior to the
tapering of bupropion and while on concomitant medication with venlafaxine. The 11 moder-
ate AEs included a mild to moderate increase in chorea and gait disorder (7 on bupropion/4
on placebo), an increase in irritability (1 on bupropion/6 on placebo), concentration difficul-
ties (3 on placebo), a sleeping disorder (2 on bupropion), agitation and restlessness (1 on
bupropion/1 on placebo), and an increase of perseverative thinking (1 on placebo). One study
participant developed disinhibition, another hyperphagia with an increase of 20 kg of body
weight while on bupropion. No participant developed active suicidality (answer “yes” to ques-
tions 4 and 5 of the “suicidal ideation” section of the C-SSRS), or indicated suicidal ideation
upon questioning by the clinical investigators.
Bupropion does not change apathy in HD as quantified by the AES-I
Comparing the primary outcome variable between the treatment groups using the linear
mixed model adjusting for baseline, there was a slight but statistically non-significant change
of the AES-I score due to bupropion treatment, which amounted to -0.81 (95% CI = -3.12,
1.52) in the full analysis set, and to -0.09 (95% CI = -2.56, 2.39) in the per protocol set Table 2.
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In any case, this level of change had no clinical relevance (defined as a change of 10 points
or more on the AES, cf. Materials & methods). The results did not change when using multiple
imputations to take missing values into account. Including random effects for the site pro-
duced a corresponding variance of random effects equal to zero, showing that there was no rel-
evant heterogeneity between sites. When we grouped the AES questions according to the three
major apathy syndrome domains (cognitive, behavioral, emotional) and analyzed them sepa-
rately, we still failed to observe a significant treatment effect on any of the three apathy
domains. However, when looking at each AES question separately, a significant treatment
effect was observed for question 2 “he/she get things done during the day” (-0.22 [95% CI =
-0.44, 0.01; p<0.05]).
Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pone.0173872.g001
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Bupropion does not change apathy in HD as quantified by the AES-S,
AES-C, NPI-Apathy or UHDRS-Apathy
For the secondary outcome parameters used to quantify apathy in this study, we observed a
slight treatment effect of bupropion measured by the AES-C (-1.26 [95% CI = -3.7, 1.2]), the
NPI-Apathy (-0.53 [95% CI = -1.6, 0.5]) and the UHDRS-Apathy (-0.71 [95% CI = -2, 0.6]),
none of which were statistically significant or clinically relevant Table 2. The study participants
Table 1. Demographic data and neuropsychiatric profiles (full analysis set).
Group 1 (bupropion/placebo)b Group 2 (placebo/bupropion)b
Number of participantsa 20 20
Age, years (mean ± SD)c 54.6 ± 8.5 54.3 ± 10.7
Males (number) 11 15
Weight, kg (mean ± SD) 78.4 ± 14.4 80.7 ± 18.7
BMI (mean ± SD) 25.1 ± 3.2 26.5 ± 5.2
CAG repeats (mean ± SD) 43.6 ± 2.3 43.9 ± 3.7
Duration of disease (years) 8.4 ± 3.6 5.5 ± 2.4d p<0.05
Concomitant medication with tiapride 11 11
UHDRS-Motor (mean ± SD) 39.3 ± 12.3 34.1 ± 12.6e
TFC (mean ± SD) 7.40 ± 2.7 8.8 ± 3.5
Apathy
AES-I (mean ± SD) 36.4 ± 7.9 34.2 ± 7.7
AES-S (mean ± SD) 29.3 ± 4 22.7 ± 8.6e, *
AES-C (mean ± SD) 36.0 ± 6.9 32.6 ± 7.9e, *
NPI-Apathy (mean ± SD) 8.8 ± 2.1 8.7 ± 2.1
UHDRS-Apathy (mean ± SD) 10 ± 2 9.4 ± 3
Depression/irritability
NPI-Depression (mean ± SD) 0.7 ± 1.1 0.8 ± 1
HADS-Depression (mean ± SD) 9.7 ± 4.6e 8.2 ± 4.1
NPI-Irritability (mean ± SD) 1.5 ± 1.9 2.2 ± 2.1
SIS (mean ± SD) 5.1 ± 3.1e 6.1 ± 4.1
Cognition
Stroop interference (mean ± SD) 22.1 ± 9 20.5 ± 10.6
SDMT (mean ± SD) 19.5 ± 8.6 22.1 ± 12
VFT (mean ± SD) 17.3 ± 12.2 22.3 ± 14.0
MMSE (mean ± SD) 26.9 ± 2.7 26.4 ± 3
Distress caregiver
NPI-D (apathy) (mean ± SD) 3.3 ± 1.0 3.5 ± 1.0
* AES-S vs. AES-I: t (df = 38) = -6.0504, p< 0.001, AES-S vs. AES-C: t (df = 38) = -5.6101, p-value = <0.001
aN includes all randomized patients
bPatients were allocated to group1 (1st treatment episode: bupropion, followed by washout and crossover, followed by 2nd treatment episode: placebo) or
group 2 (1st treatment episode: placebo, followed by washout and crossover, followed by 2nd treatment episode: bupropion).
cValues are given as mean ± SD (standard deviation)
dn = 18 (2 missing values)
en = 19 (1 missing value)
Abbreviations: BMI = Body mass index; UHDRS = Unified Huntington’s Disease Rating Scale; TFC = Total Functional Capacity; AES-I = Apathy Evaluation
Scale-informant (a friend or family member familiar with the daily activities of the subject); AES-S = AES-self; AES-C = AES-clinician;
NPI = Neuropsychiatric Inventory; HADS = Hospital Anxiety and Depression Scale; SIS = Snaith Irritability Scale; SDMT = Symbol Digit Modalities Test;
VFT = Verbal Fluency Test; MMSE = Mini Mental State Examination
https://doi.org/10.1371/journal.pone.0173872.t001
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themselves rated a reduction of apathy in the AES-S (-2.23 [95% CI = -4.9, 0.4]), which was
not significant or clinically relevant Table 2. When we grouped the AES-C and AES-S ques-
tions according to the three major apathy syndrome domains, we again did not observe a sig-
nificant treatment effect on any of the three apathy domains. Looking at the questions
separately, a significant bupropion treatment effect was revealed for question 17 “he/she has
initiative” of the AES-C (- 0.25 [95% CI = -0.5, 0; p<0.05]).
Bupropion does not influence motor performance, irritability, cognition,
or function in HD
No significant changes in irritability (HADS-SIS, NPI-Irritability) or motor function
(UHDRS-motor) due to treatment with bupropion were observed Table 2. This was somewhat
surprising as some clinical investigators noted an increase in irritability and chorea in some
study participants during the trial, as has been described in a case series. However, this could
not be attributed to bupropion after unblinding of the trial. Cognition, in particular executive
function, did not improve under medication with bupropion. Moreover, the UHDRS-Func-
tion assessment tool and the UHDRS-Independence scale did not reveal any significant
changes in the activities of daily living as a result of bupropion treatment Table 2. Finally,
Table 2. No change of apathy, irritability, cognition or function after 10 weeks of treatment with bupropion.
Full analysis set Per protocol set
Treatment effect [CI] p-value Treatment effect [CI] p-value
Apathy
AES-Ia -0.81 [-3.1, 1.5] 0.5 -0.09 [-2.6, 2.4] 0.9
AES-S -2.15 [-4.6, 0.3] 0.1 -2.23 [-4.9, 0.4] 0.1
AES-C -1.64 [-3.9, 0.7] 0.2 -1.26 [-3.7, 1.2] 0.3
NPI-Apathy -0.79 [-1.8, 0.2] 0.1 -0.53 [-1.6, 0.5] 0.3
UHDRS-Apathy -0.88 [-2.2, 0.4] 0.2 -0.71 [-2, 0.6] 0.3
Depression/irritability
NPI-Depression -0.62 [-1.3, 0.04] 0.07 -0.65 [-1.4, 0.1] 0.1
HADS-Depression 0.09 [-1.3, 1.5] 0.9 -0.16 [-1.7, 1.4] 0.8
NPI-Irritability 0.01 [-0.7, 0.8] 1 0.00 [-0.8, 0.8] 1.0
SIS (irritability) -0.07 [-1.1, 1] 0.9 -0.20 [-1.3, 0.9] 0.7
Cognition
Stroop (interference) -0.03 [-1.9, 1.7] 1 0.38 [-1.3, 2] 0.6
SDMT 1.30 [-0.1, 2.7] 0.1 1.26 [-0.1, 2.6] 0.1
VFT -0.16 [-2.1, 1.8] 0.9 -0.41 [-2.4, 1.6] 0.7
MMSE 0.59 [-0.2, 1.4] 0.1 0.77 [-0.1, 1.6] 0.1
Distress caregiver
NPI-D (apathy) 0.14 [-0.3, 0.6] 0.5 0.21 [-0.2, 0.7] 0.3
Functional scores
UHDRS-Motor -0.64 [-2.7, 1.5] 0.5 -0.45 [-2.7, 1.8] 0.7
TFC 0.33 [-0.1, 0.7] 0.1 0.38 [0, 0.8] 0.07
UHDRS-Function 0.29 [-0.3, 0.9] 0.3 0.29 [-0.3, 0.9] 0.4
UHDRS-Independence -0.53 [-2.2, 1.1] 0.5 -0.59 [-2.3, 1.2] 0.5
aResults are given as treatment effect and 95% confidence interval. The primary outcome parameter is shown in bold. Inferential statistical evaluation of
the primary and secondary outcome parameters were based on a linear mixed effects model with the AES-I score as dependent variable using only the first
baseline before treatment. The significance level was set to 0.05.
https://doi.org/10.1371/journal.pone.0173872.t002
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caregiver distress was not alleviated by treatment of apathetic HD patients with bupropion
Table 2. Taken together, there was no change of any clinical secondary outcome parameter as
a result of bupropion treatment.
Trial participation/placebo effects alleviate symptoms of apathy
Irrespective of the intervention (bupropion or placebo), informants and clinical investigators
observed a significant improvement of the symptoms of apathy (AES-I, AES-C) or the apathy
syndrome (NPI-Apathy, UHDRS-Apathy) predominantly during the first treatment period
Table 3. Notably, this was not observed in the AES-S scores.
Study participants also rated their symptoms of apathy as significantly less severe than the
caregivers or the clinical investigators Table 1. There was also a tendency of a period effect
when grading irritability by the UHDRS-Behavior, the SIS or the NPI. However, the observa-
tions were not consistent between instruments, and the changes in irritability scores were too
low to have any clinical relevance (data not shown).
Bupropion does not influence brain structure, brain response or brain
connectivity
The analyses of structural and functional MRI data revealed no significant treatment effects.
We only found a trend toward a decline in the right orbitofrontal cortex gray matter for the
bupropion group (ANOVA p = 0.088), and an increase in functional connectivity between the
left and right ventral striatum for the bupropion group (ANOVA p = 0.068) S1, S2 and S3
Tables.
Discussion
ACTION-HD is the first randomised controlled clinical trial on the treatment of apathy in
HD. We did not find a clinically significant effect of a 10-week treatment course with bupro-
pion (at a dose of 300 mg per day) on the severity of apathy in HD based on assessments by
informant, study participant and clinical investigator using the AES. Two further informant-
based assessment tools (NPI-Apathy and UHDRS-Apathy) also failed to reveal a treatment
effect of bupropion.
A concern when designing this trial was the lack of robust longitudinal data on the severity
of apathy in HD, since no ‘gold standard tool’ for the assessment of apathy exists in general
[30], and for HD in particular. We chose the SCIA-D as a screening instrument for the
Table 3. Change of apathy after the first treatment period suggests activation through trial participation.
Instrument Score (min/max) a Baselineb Period 1b Period 2b p-value
AES-I 0–54 35.3 ± 7.8 32.6 ± 9.5 31.1 ± 10.3 < 0.005c
AES-S 0–54 26.1 ± 8.6 26.5 ± 8.3 26.3 ± 9.5 0.9
AES-C 0–54 34.4 ± 7.5 32 ± 8.4 31 ± 9.3 < 0.05
NPI-Apathy 1–12 8.6 ± 2.5 7 ± 3 6.7 ± 3.3 < 0.001
UHDRS-Apathy 0–16 9.7 ± 2.5 8.7 ± 3.17 7.9 ± 3.9 < 0.05
NPI-D Apathy 0–5 3.35 ± 1 3.1 ± 1.1 2.7 ± 1.2 < 0.01
aMinimum and maximum values of the instruments used to grade apathetic symptoms (AES), apathy as syndrome (NPI, UHDRS) or caregiver distress due
to apathy (NPI-D)
bValues are given for the full analysis set as means ± SD (standard deviation)
cp = 0.14 after multiple imputation to take missing values into account
https://doi.org/10.1371/journal.pone.0173872.t003
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diagnosis of apathy, and the AES as a baseline and follow-up tool to measure the severity of
apathy. The SCIAD-D is based on the criteria of Starkstein et al. [25], which were recently
incorporated into the consensus criteria for the diagnosis of apathy proposed by an interna-
tional task force [31]. The criteria refer to the prior functional status of the study participant,
which we judged to be more appropriate than an arbitrarily determined baseline cutoff score.
The AES is the most widely used rating scale for the symptoms of apathy. Clinical studies have
also relied on single item measures like the UHDRS-Behavior or the NPI. Only recently, the
AES has been validated in HD [32]. Importantly, confounding factors like lack of awareness
[33], comorbid depression, motor symptoms, or side effects of concomitant medication have
to be considered when evaluating apathy in HD.
The reasons for choosing the AES as the primary rating scale in the ACTION-HD trial
included i. the availability of a validated German version [34], ii. the possibility of separate rat-
ings by participant, informant and clinician, iii. the good inter-rater reliability for the AES-C
[35], iv. the separate evaluation of all three domains of apathy [2, 26], v. the provision of per-
formance guidelines by the author, allowing for further standardization [27], vi. the suitability
of the AES for statistical evaluation due to the 4-point Likert scale, vii. the reasonable length
and complexity, allowing for informative answers by cognitively impaired study participants.
Based on previous reliability studies in AD, the test-retest reliability is 0.94 for the AES-I, 0.88–
0.89 for the AES-C, and 0.76 for the AES-S [27, 36]. Power calculations were performed using
longitudinal AES data from a recently published HD cohort [32]. AES threshold scores have
been suggested for AD with a range from 30 to 41.5 [37], but also for conditions like trau-
matic brain injury [38]. Baseline scores of some of our patients were below these values
Table 1, but there was no doubt about the presence of apathy in these study participants based
on the SCIA-D as well as on the clinical assessments. Moreover, we found a mean NPI apathy
score of 8.6 at baseline in our study. NPI apathy scores above 4 have recently been suggested to
define clinically significant apathy in dementia [39].
We chose the informant version of the AES, the AES-I score, as the primary outcome vari-
able since we assumed that HD patients rate their symptoms of apathy less severe than their
caregivers or physicians [40, 41]. In HD, like in other neuropsychiatric diseases with frontal
pathology, lack of insight into symptoms and functional capacities is common [42, 43]. Marin
originally evaluated the AES in several diseases, including AD [26, 27], where he observed that
patients graded the symptoms of apathy as less severe than their caregivers or clinicians. An
association with frontal dysfunction has been suggested also for AD [44]. On the other hand,
one has to consider that caregivers may be biased by the burden that the patient’s apathy
bestows on them [45]. As expected, participants of Action-HD rated their symptoms of apathy
as significantly less severe than their caregivers or the clinical investigator. In addition, a signif-
icant period effect was observed for AES-I and AES-C but not for AES-S scores Tables 1 and 3.
In contrast to these findings, Mason and Barker at the University of Cambridge (UK) did not
find a significant difference between AES-I and AES-S sores during an observation period of
19 months on average [32]. An explanation for this discrepancy could be that we physically
separated patients and informants when performing the AES, as we previously observed that
patients may adapt their judgements to the ratings of the caregivers when assessed in the same
setting. In addition, the relative number of participants with a TFC score between 7 and 10
was small in the Cambridge study, whereas the mean TFC scores in our study were 7.4 and 8.8
in the intervention groups, respectively. Of the 40 patients rated as apathetic by their infor-
mants, 21 were lost to follow up in the Cambridge study, which creates a bias. Moreover, we
excluded patients with dopamine-depleting drugs, and patients with comorbid depression in
our study in order to reduce confounding effects. This has also recently been recommended by
Cummings and coworkers [39]. However, we do acknowledge that HD patients with both
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depression and apathy may constitute a subgroup that responds better to bupropion than HD
patients with apathy alone.
To quantify the affective-emotional components of apathy we additionally used an estab-
lished gambling task to measure reward perception as one of the major preconditions for moti-
vation [24, 29, 46]. DA is thought to be involved in reward and motivation, possibly through
modification of the mesolimbic and mesocortical pathways, as well as the orbitomedial PFC-
striatal projections. The loss of DA receptor 1 and 2 expression in fronto-striatal circuits was
proposed as a key pathophysiological mechanism of apathy in HD [7, 8]. Concurrent with the
clinical results, we did not detect significant effects of bupropion treatment on brain responses
and functional connectivity during reward processing in apathetic HD patients in our explor-
atory fMRI analysis. However, it is difficult to draw any conclusion from the small sample size.
When considering the study duration, we feel that 8 weeks on the full dose of bupropion
should have been sufficient for the detection of a potential treatment effect. The duration of
most randomized CTs on apathy in neurodegenerative diseases is between 6 and 12 weeks. In
fact, Cummings et al. recommended a study duration of 8 to 12 weeks when designing clinical
trials for apathy in neurodegenerative diseases since the worsening of apathy in both the
verum and placebo arms may result in an underestimation of an initial treatment effect in the
intervention arm if the intervention period would be extended beyond 12 weeks [39].
It is possible that bupropion did not reach sufficient concentrations within the central
nervous system at a daily dose of 300mg. However, we felt that daily doses of 450 mg could
be problematic in advanced stages of HD as the risk of seizures, suicidality and irritability
may increase.
HD patients in more advanced disease stages often require symptomatic treatment [19].
We cannot exclude the possibility that concomitant medication in some of the study partici-
pants may have aggravated apathy or mitigated the effect of bupropion. This is particularly
true for tiapride, a dopamine D2 and D3 receptor antagonist, which is commonly used to treat
chorea in Germany. A type 2 error may also result from low sensitivity of the available instru-
ments for grading apathy. In the case of the AES, the poor differentiation between the answers
2 (“slightly characteristic”) and 3 (“somewhat characteristic”) on the four point Likert scale
may reduce sensitivity. It is noteworthy that the validation of the AES in HD is still incomplete
[41]. Our trial adds important data for this process.
Many recent drug trials in HD, e.g. the MermaiHD study [47] and the deutetrabenazine
trial [48], have detected significant placebo effects. Interestingly, Cubo et al. observed a signifi-
cant placebo effect on behavior, but not on motor symptoms or cognition in a large multicen-
ter drug trial in HD [49]. This effect persisted over 3 years and was prominent if depression
was absent. In Action-HD, we observed an improvement of the primary outcome measure
AES-I for all study participants predominantly prior to crossover. This was replicated for the
clinician-rated AES-C score. Study participants were informed about the crossover design.
Since we compared period 1 and 2 data with the original baseline, the results suggest, that
study participation/placebo effects have a positive impact on the severity of apathy. (cf.
Table 3). Notably, the study participants themselves did not rate any improvement on the
AES-S. These important findings indicate that our study was not underpowered to detect sig-
nificant changes of apathy using the AES and that, when studying apathy in HD, activation by
study participation should be considered when interpreting trial results.
Conclusion
The ACTION-HD trial suggests that bupropion does not influence the severity of apathy in
non-depressed HD patients as quantified by the AES and other behavioral assessment tools.
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We observed a significant period effect irrespective of the intervention (bupropion or pla-
cebo). These findings highlight the general need for controlled symptomatic treatment trials
in HD.
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